Immunotherapy questions in melanoma

Immuno-Oncology Insights 2022; 3(3), 51–56


Published: 10 February 2022
Michael Postow

David McCall, Editor, BioInsights, speaks to Michael Postow, Chief of the Melanoma Service, Associate Attending Physician, Memorial Sloan Kettering Cancer Center.

Michael Postow is the Chief of the Melanoma Service and an Associate Attending Physician at Memorial Sloan Kettering Cancer Center. He was involved in the clinical development of the nivolumab + ipilimumab combination and led the first randomized trial of combination immune checkpoint inhibition, resulting in its FDA approval in 2015. He has written papers on immunotherapy toxicities and combining systemic immunotherapies with other treatments such as radiotherapy. He enjoys skiing, outdoor activities, and trying to keep up with his two toddlers.